While TGF-β2 is a positive regulator of hematopoiesis and normal cardiac function, and TGF-β1 and -β3 are negative regulators of hematopoiesis, thus makes the T22d35-Fc-fusion a very attractive therapeutic modality for the treatment of myelodysplastic syndrome (MDS) associated anemia. This evidence concerns the gene TGFB2 and myelodysplastic syndrome.